Hereditary Angioedema Therapeutics Market Report 2026
Download Free Sample Buy Now
Hereditary Angioedema Therapeutics Market Global Report 2026 Market Report Infographic Image
Item added to cart!

Published : February 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF
Purchase This Report

Hereditary Angioedema Therapeutics Market Report 2026

Global Outlook – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-Demand) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Hereditary Angioedema Therapeutics Market Overview

• Hereditary Angioedema Therapeutics market size has reached to $7.77 billion in 2025

• Expected to grow to $19.03 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%

• Growth Driver: Growth Of The Hereditary Angioedema Therapeutics Market Driven By Increasing Healthcare Expenditure

• Market Trend: Innovative Oral Treatments Transforming Management of Hereditary Angioedema

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hereditary Angioedema Therapeutics Market?

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics are C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, others. C1 Esterase Inhibitor refers to a protein called that is present in the fluid portion of blood and it regulates the complement system's protein C1, which goes by the name of C1. The therapeutics are administered through intravenous, subcutaneous, and oral, distributed via hospital pharmacy, retail pharmacy, and others. The application of hereditary angioedema therapeutics include prophylaxis and on-demand.

Hereditary Angioedema Therapeutics Market Global Report 2026 Market Report bar graph

What Is The Hereditary Angioedema Therapeutics Market Size and Share 2026?

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from $7.77 billion in 2025 to $9.27 billion in 2026 at a compound annual growth rate (CAGR) of 19.3%. The growth in the historic period can be attributed to limited awareness about hae, dependency on hospital-based therapy, fewer approved therapeutic options, reliance on intravenous administration, low prevalence diagnosis rates.

What Is The Hereditary Angioedema Therapeutics Market Growth Forecast?

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $19.03 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to growth in recombinant c1 esterase inhibitors, adoption of subcutaneous delivery methods, rising prophylactic therapy usage, expansion of specialty pharmacy channels, increasing investment in rare disease research. Major trends in the forecast period include personalized therapy development, increased orphan drug approvals, advancements in subcutaneous drug delivery, development of on-demand treatment options, expansion of hospital and retail pharmacy networks.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Hereditary Angioedema Therapeutics Market Segmentation

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-Demand

What Is The Driver Of The Hereditary Angioedema Therapeutics Market?

The increasing healthcare expenditure is expected to boost the growth of the hereditary angioedema therapeutics market going forward. Healthcare expenditure refers to the total amount of resources, including financial resources, spent on healthcare goods and services within a specific period in a given geographical area. Greater healthcare expenditure allows for increased investment in research and development activities focused on understanding the underlying causes of hereditary angioedema and developing innovative therapeutic solutions. For instance, in June 2025, according to the Centers for Medicare & Medicaid Services (CMS), the US-based federal agency, National Health Expenditure (NHE) grew 7.5% to $4.9 trillion in 2023, or $14,570 per person, and accounted for 17.6% of Gross Domestic Product (GDP). Hospital expenditures grew 10.4% to $1,519.7 billion in 2023, faster than the 3.2% growth in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the hereditary angioedema therapeutics industry.

Key Players In The Global Hereditary Angioedema Therapeutics Market

Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.

Global Hereditary Angioedema Therapeutics Market Trends and Insights

Major companies operating in the hereditary angioedema (HAE) therapeutics market are developing innovative treatments, such as oral plasma kallikrein inhibitors, to enhance patient management and provide effective, on-demand options for alleviating HAE attacks, thereby improving overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are drugs taken by mouth that inhibit the enzyme plasma kallikrein, helping to manage and reduce the severity of hereditary angioedema attacks. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US. Food and Drug Administration of New drug application for Sebetralstat, aiming to offer HAE patients a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution meets the growing demand for fast, effective oral treatments that can be administered immediately during an hereditary angioedema attack.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market?

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC for an undisclosed amount. This acquisition strengthens Takeda's growing late-stage pipeline to expand its portfolio and patient impact across multiple indications and maintains strong global growth over the medium to long term. Nimbus Lakshmi, a fully-owned subsidiary of Nimbus Therapeutics, is a US-based company that provides Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Regional Insights

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, and management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano-filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hereditary Angioedema Therapeutics Market Report 2026?

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Hereditary Angioedema Therapeutics Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $9.27 billion
Revenue Forecast In 2035 $19.03 billion
Growth Rate CAGR of 19.3% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Drug Class, Route of Administration, Distribution Channel, Application
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sob
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Hereditary Angioedema Therapeutics Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Hereditary Angioedema Therapeutics Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Hereditary Angioedema Therapeutics Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Hereditary Angioedema Therapeutics Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Digitalization, Cloud, Big Data & Cybersecurity

4.1.3 Artificial Intelligence & Autonomous Intelligence

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Personalized Therapy Development

4.2.2 Increased Orphan Drug Approvals

4.2.3 Advancements In Subcutaneous Drug Delivery

4.2.4 Development Of On-Demand Treatment Options

4.2.5 Expansion Of Hospital And Retail Pharmacy Networks

5. Hereditary Angioedema Therapeutics Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Clinics

5.3 Retail Pharmacies

5.4 Home Healthcare Providers

5.5 Oncology And Rare Disease Centers

6. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hereditary Angioedema Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Hereditary Angioedema Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Hereditary Angioedema Therapeutics Market Size, Comparisons And Growth Rate Analysis

7.3. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hereditary Angioedema Therapeutics Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hereditary Angioedema Therapeutics Market Segmentation

9.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

9.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Intravenous, Subcutaneous, Oral

9.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

9.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Prophylaxis, On-Demand

9.5. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

C1 Esterase Inhibitor Therapies

9.6. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Selective Bradykinin B2 Receptor Antagonist Therapies

9.7. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Kallikrein Inhibitor Therapies

9.8. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Other HAE Drug Classes

10. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

10.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hereditary Angioedema Therapeutics Market

11.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hereditary Angioedema Therapeutics Market

12.1. China Hereditary Angioedema Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hereditary Angioedema Therapeutics Market

13.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hereditary Angioedema Therapeutics Market

14.1. Japan Hereditary Angioedema Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hereditary Angioedema Therapeutics Market

15.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hereditary Angioedema Therapeutics Market

16.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hereditary Angioedema Therapeutics Market

17.1. South Korea Hereditary Angioedema Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hereditary Angioedema Therapeutics Market

18.1. Taiwan Hereditary Angioedema Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hereditary Angioedema Therapeutics Market

19.1. South East Asia Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hereditary Angioedema Therapeutics Market

20.1. Western Europe Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hereditary Angioedema Therapeutics Market

21.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hereditary Angioedema Therapeutics Market

22.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hereditary Angioedema Therapeutics Market

23.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hereditary Angioedema Therapeutics Market

24.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hereditary Angioedema Therapeutics Market

25.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hereditary Angioedema Therapeutics Market

26.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hereditary Angioedema Therapeutics Market

27.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hereditary Angioedema Therapeutics Market

28.1. North America Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hereditary Angioedema Therapeutics Market

29.1. USA Hereditary Angioedema Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hereditary Angioedema Therapeutics Market

30.1. Canada Hereditary Angioedema Therapeutics Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hereditary Angioedema Therapeutics Market

31.1. South America Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hereditary Angioedema Therapeutics Market

32.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hereditary Angioedema Therapeutics Market

33.1. Middle East Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hereditary Angioedema Therapeutics Market

34.1. Africa Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Segmentation By Route of Administration, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hereditary Angioedema Therapeutics Market Regulatory and Investment Landscape

36. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

36.1. Hereditary Angioedema Therapeutics Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Hereditary Angioedema Therapeutics Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Hereditary Angioedema Therapeutics Market Company Profiles

36.3.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. BioCryst Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis

37. Hereditary Angioedema Therapeutics Market Other Major And Innovative Companies

KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals, PharmAthene Inc., BioMarin Pharmaceutical Inc.

38. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

40. Hereditary Angioedema Therapeutics Market High Potential Countries, Segments and Strategies

40.1 Hereditary Angioedema Therapeutics Market In 2030 - Countries Offering Most New Opportunities

40.2 Hereditary Angioedema Therapeutics Market In 2030 - Segments Offering Most New Opportunities

40.3 Hereditary Angioedema Therapeutics Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Hereditary Angioedema Therapeutics Market, Overview Of Key Products - Product Examples
  • Table 2: Global Hereditary Angioedema Therapeutics Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Hereditary Angioedema Therapeutics Market, Supply Chain Analysis
  • Table 4: Global Hereditary Angioedema Therapeutics Market, Major Raw Material Providers
  • Table 5: Global Hereditary Angioedema Therapeutics Market, Major Resource Providers
  • Table 6: Global Hereditary Angioedema Therapeutics Market, Major Manufacturers (Suppliers)
  • Table 7: Global Hereditary Angioedema Therapeutics Market, Major Distributors And Channel Partners
  • Table 8: Global Hereditary Angioedema Therapeutics Market, Key Technologies & Future Trends
  • Table 9: Global Hereditary Angioedema Therapeutics Market, Major Trends
  • Table 10: Global Hereditary Angioedema Therapeutics Market, Major End Users
  • Table 11: Global Hereditary Angioedema Therapeutics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Hereditary Angioedema Therapeutics Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Hereditary Angioedema Therapeutics Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Hereditary Angioedema Therapeutics Market - TAM, US$ Billion, 2025
  • Table 15: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Global Hereditary Angioedema Therapeutics Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 98: Global Hereditary Angioedema Therapeutics Market - Company Scoring Matrix
  • Table 99: Sanofi S.A. Financial Performance
  • Table 100: Pharming Healthcare Inc. Financial Performance
  • Table 101: Attune Pharmaceuticals Inc. Financial Performance
  • Table 102: BioCryst Pharmaceuticals Inc. Financial Performance
  • Table 103: CSL Behring LLC Financial Performance
  • Table 104: Global Hereditary Angioedema Therapeutics Market, Competitive Benchmarking (In USD Billions)
  • Table 105: Global Hereditary Angioedema Therapeutics Market, Competitive Dashboard
  • Table 106: Global Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 107: Global, Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Table 108: Global, Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030
  • Table 109: Global, Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global Hereditary Angioedema Therapeutics Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Hereditary Angioedema Therapeutics Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Hereditary Angioedema Therapeutics Market, Supply Chain Analysis
  • Figure 4: Global Hereditary Angioedema Therapeutics Market, Major Raw Material Providers
  • Figure 5: Global Hereditary Angioedema Therapeutics Market, Major Resource Providers
  • Figure 6: Global Hereditary Angioedema Therapeutics Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Hereditary Angioedema Therapeutics Market, Major Distributors And Channel Partners
  • Figure 8: Global Hereditary Angioedema Therapeutics Market, Key Technologies & Future Trends
  • Figure 9: Global Hereditary Angioedema Therapeutics Market, Major Trends
  • Figure 10: Global Hereditary Angioedema Therapeutics Market, Major End Users
  • Figure 11: Global Hereditary Angioedema Therapeutics Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Hereditary Angioedema Therapeutics Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Hereditary Angioedema Therapeutics Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Hereditary Angioedema Therapeutics Market - TAM, US$ Billion, 2025
  • Figure 15: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Global Hereditary Angioedema Therapeutics Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 98: Global Hereditary Angioedema Therapeutics Market - Company Scoring Matrix
  • Figure 99: Sanofi S.A. Financial Performance
  • Figure 100: Pharming Healthcare Inc. Financial Performance
  • Figure 101: Attune Pharmaceuticals Inc. Financial Performance
  • Figure 102: BioCryst Pharmaceuticals Inc. Financial Performance
  • Figure 103: CSL Behring LLC Financial Performance
  • Figure 104: Global Hereditary Angioedema Therapeutics Market, Competitive Benchmarking (In USD Billions)
  • Figure 105: Global Hereditary Angioedema Therapeutics Market, Competitive Dashboard
  • Figure 106: Global Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 107: Global, Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030
  • Figure 108: Global, Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), Segmentation By Route of Administration, 2025 – 2030
  • Figure 109: Global, Hereditary Angioedema Therapeutics Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Read More About Advanced Therapy Medicinal Products Industry Poised for Rapid Expansion, Projected to Hit $104.43 Billion by 2029

Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

Read More About Global Insights: Androgen Deprivation Therapy Market Expected to Surpass $10.49 Billion by 2029

2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Anti-CD20 Monoclonal Antibodies Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

Read More About Future Projections: Anti-D Immunoglobulin Market to Reach $3.34 Billion by 2029 at 6.6% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Hereditary Angioedema Therapeutics Market Report 2026 - Global Outlook – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administr...

Angina Pectoris Drugs Market Report 2026 - Global Outlook – By Drugs (Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins), By Indication (Stable Angina...

Angina Market Report 2026 - Global Outlook – By Type (Angina Pectoris, Unstable Angina, Prinzmetal Angina, Other Types), By Treatment (Lifestyle Changes, Medications, Angioplasty And Stenting, Coronary Bypass Surgery, Ot...

Biopsy Devices Market Report 2026 - Global Outlook – By Product Type (Needle-Based Biopsy Guns, Biopsy Forceps, Biopsy Guidance Systems, Biopsy Needles, Other Products), By Image Guiding Technology (MRI-Guided Biopsy, St...

Angina Pectoris Drugs Market Report 2026 - Global Outlook – By Drugs (Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins), By Indication (Stable Angina...

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report 2026 - Global Outlook – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Tes...

Hereditary Cancer Testing Market Report 2026 - Global Outlook – By Test Type (Multi Panel Test, Single-Site Genetic Test), By Indication (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications), By End user ...

Peripheral Arterial Disease Market Report 2026 - Global Outlook – By Treatment Type (Devices, Catheters, Drugs, Other Types), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By End User (Ho...

Frequently Asked Questions

The Hereditary Angioedema Therapeutics market was valued at $7.77 billion in 2025, increased to $9.27 billion in 2026, and is projected to reach $19.03 billion by 2030.

The global Hereditary Angioedema Therapeutics market is expected to grow at a CAGR of 19.7% from 2026 to 2035 to reach $19.03 billion by 2035.

Some Key Players in the Hereditary Angioedema Therapeutics market Include, Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc. .

Major trend in this market includes: Innovative Oral Treatments Transforming Management of Hereditary Angioedema. For further insights on this market. request a sample here

North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us